Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range?

Maciej Kabat, Ivan Bobkov, Suneel Kumar, Martin Grumet, Maciej Kabat, Ivan Bobkov, Suneel Kumar, Martin Grumet

Abstract

The number of clinical trials using mesenchymal stem cells (MSCs) has increased since 2008, but this trend slowed in the past several years and dropped precipitously in 2018. Previous reports have analyzed MSC clinical trials by disease, phase, cell source, country of origin, and trial initiation date, all of which can be downloaded directly from ClinicalTrials.gov. We have extended analyses to a larger group of 914 MSC trials reported through 2018. To search for potential factors that may influence the design of new trials, we extracted data on routes of administration and dosing from individual ClinicalTrials.gov records as this information cannot be downloaded directly from the database. Intravenous (IV) injection is the most common, least invasive and most reproducible method, accounting for 43% of all trials. The median dose for IV delivery is 100 million MSCs/patient/dose. Analysis of all trials using IV injection that reported positive outcomes indicated minimal effective doses (MEDs) ranging from 70 to 190 million MSCs/patient/dose in 14/16 trials with the other two trials administering much higher doses of at least 900 million cells. Dose-response data showing differential efficacy for improved outcomes were reported in only four trials, which indicated a narrower MED range of 100-150 million MSCs/patient with lower and higher IV doses being less effective. The results suggest that it may be critical to determine MEDs in early trials before proceeding with large clinical trials.

Keywords: ClinicalTrials.gov; dose; intravenous; mesenchymal stromal cell.

Conflict of interest statement

M.G. declared equity in CytoStormRx LLC but there is no conflict of interest. The other authors indicated no potential conflicts of interest.

© 2020 The Authors. Stem Cells Translational Medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.

Figures

Figure 1
Figure 1
Number of new mesenchymal stem cell (MSC) clinical trials registered in each year at http://ClinicalTrials.gov divided by clinical phase (A). B, Data in (A) represented in a graph of the 3 phases plotted separately
Figure 2
Figure 2
Number of trials using MSCs from different sources divided by phase. A, UC and placenta derived MSC are only allogenic. Autologous MSC were derived mainly from BM and adipose tissue with small numbers from other sources including dental pulp, gingiva, oral mucosa, perinatal tissue, peripheral blood, skin, menstrual blood, and stromal vascular fraction designated as other. B, Number of new MSC autologous and allogenic trials in each year. BM, bone marrow; MSC, mesenchymal stem cell; UC, umbilical cord
Figure 3
Figure 3
Number of clinical trials using proprietary MSC and involving companies. A, Graph of number of new trials using proprietary (blue) and non‐proprietary (white) MSC shown for four major sources. Small number of additional trials using MSC from dental pulp, oral mucosa, menstrual blood, and stromal vascular fraction have been included in the category called other. B, Number of new trials recorded in each year conducted by, or sponsored by, companies with all sources of MSCs. BM, bone marrow; MSC, mesenchymal stem cell; UC, umbilical cord
Figure 4
Figure 4
Mesenchymal stem cell (MSC) clinical trials by disease category subdivided by phase. The 14 disease categories shown account for >90% of the trials in our database. The remaining trials were defined as other
Figure 5
Figure 5
Routes of MSC administration in clinical trials subdivided by phases and dosing. A, Trials were divided into the 8 most commonly used routes with the remaining routes defined as other. Intravenous (IV) is by far the largest group. Intra‐cardiac (IC), intra‐articular (IAT), intra‐muscular (IM), intra‐osseous (IO), intra‐thecal (IT), intra‐arterial (IA). Implant includes MSC embedded in biological matrices or synthetic materials. B, Doses of MSC using different routes of administration in clinical trials using Box‐and‐Whisker plot showing the average (dot), median (horizontal line), 10th to 90th percentile whiskers, and 25th to 75th percentile boxes (*P < .05, **P < .02, ****P < .005). C, Disorders are divided by frequencies of different routes of MSC delivery

References

    1. Mastri M, Lin H, Lee T. Enhancing the efficacy of mesenchymal stem cell therapy. World J Stem Cell. 2014;6:82‐93.
    1. Oliveri RS, Bello S, Biering‐Sorensen F. Mesenchymal stem cells improve locomotor recovery in traumatic spinal cord injury: systematic review with meta‐analyses of rat models. Neurobiol Dis. 2014;62:338‐353.
    1. Walter J, Ware LB, Matthay MA. Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis. Lancet Respir Med. 2014;2:1016‐1026.
    1. Yoo J, Kim HS, Hwang DY. Stem cells as promising therapeutic options for neurological disorders. J Cell Biochem. 2013;114:743‐753.
    1. Lombardo E, van der Poll T, DelaRosa O, et al. Mesenchymal stem cells as a therapeutic tool to treat sepsis. World J Stem Cells. 2015;7:368‐379.
    1. Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transplant. 2016;25:829‐848.
    1. Wei X, Yang X, Han ZP, et al. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin. 2013;34:747‐754.
    1. Galipeau J, Sensebe L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22:824‐833.
    1. Panes J, Garcia‐Olmo D, Van Assche G, et al. Expanded allogeneic adipose‐derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double‐blind controlled trial. Lancet. 2016;388:1281‐1290.
    1. Caplan AI. Why are MSCs therapeutic? New data: new insight. J Pathol. 2009;217:318‐324.
    1. Friedenstein AJ, Piatetzky S II, Petrakova KV. Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol. 1966;16:381‐390.
    1. Viswanathan S, Keating A, Deans R, et al. Soliciting strategies for developing cell‐based reference materials to advance mesenchymal stromal cell research and clinical translation. Stem Cells Dev. 2014;23:1157‐1167.
    1. Bernardo ME, Fibbe WE. Safety and efficacy of mesenchymal stromal cell therapy in autoimmune disorders. Ann N Y Acad Sci. 2012;1266:107‐117.
    1. Julian K, Yuhasz N, Hollingsworth E, et al. The "Growing" reality of the neurological complications of global "Stem Cell Tourism". Semin Neurol. 2018;38:176‐181.
    1. Cagliani J, Grande D, Molmenti EP, et al. Immunomodulation by mesenchymal stromal cells and their clinical applications. J Stem Cell Regen Biol. 2017;3:1‐26.
    1. Galipeau J, Krampera M, Barrett J, et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. 2016;18:151‐159.
    1. Olsen TR, Ng KS, Lock LT, et al. Peak MSC—are we there yet? Front Med. 2018;5:178.
    1. Couto PS, Bersenev A, Verter F. The first decade of advanced cell therapy clinical trials using perinatal cells (2005‐2015). Regen Med. 2017;12:953‐968.
    1. Leibacher J, Henschler R. Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells. Stem Cell Res Ther. 2016;7:7.
    1. Jellema RK, Ophelders DR, Zwanenburg A, et al. Multipotent adult progenitor cells for hypoxic‐ischemic injury in the preterm brain. J Neuroinflammation. 2015;12:241.
    1. Gronthos S, McCarty R, Mrozik K, et al. Heat shock protein‐90 beta is expressed at the surface of multipotential mesenchymal precursor cells: generation of a novel monoclonal antibody, STRO‐4, with specificity for mesenchymal precursor cells from human and ovine tissues. Stem Cells Dev. 2009;18:1253‐1262.
    1. Veronesi F, Maglio M, Tschon M, et al. Adipose‐derived mesenchymal stem cells for cartilage tissue engineering: state‐of‐the‐art in in vivo studies. J Biomed Mater Res A. 2014;102:2448‐2466.
    1. Thirumala S, Gimble JM, Devireddy RV. Evaluation of methylcellulose and dimethyl sulfoxide as the cryoprotectants in a serum‐free freezing media for cryopreservation of adipose‐derived adult stem cells. Stem Cells Dev. 2010;19:513‐522.
    1. Hur JW, Cho TH, Park DH, et al. Intrathecal transplantation of autologous adipose‐derived mesenchymal stem cells for treating spinal cord injury: a human trial. J Spinal Cord Med. 2015;39:655‐664.
    1. Gonzalez‐Rey E, Anderson P, Gonzalez MA, et al. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut. 2009;58:929‐939.
    1. Huet O, Chin‐Dusting JP. Septic shock: desperately seeking treatment. Clin Sci (Lond). 2014;126:31‐39.
    1. Fischer UM, Harting MT, Jimenez F, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first‐pass effect. Stem Cells Dev. 2009;18:683‐692.
    1. Skyler JS, Fonseca VA, Segal KR, et al. Allogeneic mesenchymal precursor cells in type 2 diabetes: a randomized, placebo‐controlled, dose‐escalation safety and tolerability pilot study. Diabetes Care. 2015;38:1742‐1749.
    1. Packham DK, Fraser IR, Kerr PG, et al. Allogeneic mesenchymal precursor cells (MPC) in diabetic nephropathy: a randomized, placebo‐controlled, dose escalation study. EBioMedicine. 2016;12:263‐269.
    1. Golpanian S, DiFede DL, Khan A, et al. Allogeneic human mesenchymal stem cell infusions for aging frailty. J Gerontol A Biol Sci Med Sci. 2017;72:1505‐1512.
    1. Winkler T, Perka C, von Roth P, et al. Immunomodulatory placental‐expanded, mesenchymal stromal cells improve muscle function following hip arthroplasty. J Cachexia Sarcopenia Muscle. 2018;9:880‐897.
    1. Melmed GY, Pandak WM, Casey K, et al. Human placenta‐derived cells (PDA‐001) for the treatment of moderate‐to‐severe Crohn's disease: a phase 1b/2a study. Inflamm Bowel Dis. 2015;21:1809‐1816.
    1. Hess DC, Wechsler LR, Clark WM, et al. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double‐blind, placebo‐controlled, phase 2 trial. Lancet Neurol. 2017;16:360‐368.
    1. Athersys . Athersys presents data from its acute respiratory distress syndrome clinical trial at American Thoracic Society International Conference. 2019.
    1. Vangsness CT Jr, Farr J 2nd, Boyd J, et al. Adult human mesenchymal stem cells delivered via intra‐articular injection to the knee following partial medial meniscectomy: a randomized, double‐blind, controlled study. J Bone Joint Surg Am. 2014;96:90‐98.
    1. Lamo‐Espinosa JM, Mora G, Blanco JF, et al. Intra‐articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II). J Transl Med. 2016;14:246.
    1. Jo CH, Chai JW, Jeong EC, et al. Intra‐articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a 2‐year follow‐up study. Am J Sports Med. 2017;45:2774‐2783.
    1. Li MD, Atkins H, Bubela T. The global landscape of stem cell clinical trials. Regen Med. 2014;9:27‐39.
    1. European Medicines Agency . European public assessment report (EPAR) for Alofisel. Available at: . 2018.
    1. Pharmaceuticals and Medical Devices Agency . Stemirac, human (autologous) bone marrow‐derived mesenchymal stem cells. Available at: . 2015.
    1. Lee RH, Pulin AA, Seo MJ, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti‐inflammatory protein TSG‐6. Cell Stem Cell. 2009;5:54‐63.
    1. Matthay MA, Pati S, Lee JW. Concise Review: mesenchymal stem (stromal) cells: biology and preclinical evidence for therapeutic potential for organ dysfunction following trauma or sepsis. Stem Cells. 2017;35:316‐324.
    1. Byun JS, Kwak BK, Kim JK, et al. Engraftment of human mesenchymal stem cells in a rat photothrombotic cerebral infarction model: comparison of intra‐arterial and intravenous infusion using MRI and histological analysis. J Korean Neurosurg Soc. 2013;54:467‐476.
    1. Antebi B, Mohammadipoor A, Batchinsky AI, et al. The promise of mesenchymal stem cell therapy for acute respiratory distress syndrome. J Trauma Acute Care Surg. 2018;84:183‐191.
    1. Chinnadurai R, Ng S, Velu V, et al. Challenges in animal modelling of mesenchymal stromal cell therapy for inflammatory bowel disease. World J Gastroenterol. 2015;21:4779‐4787.
    1. Reger RL, Prockop DJ. Should publications on mesenchymal stem/progenitor cells include in‐process data on the preparation of the cells? Stem Cells Translational Medicine. 2014;3:632‐635.
    1. Martin I, Galipeau J, Kessler C, et al. Challenges for mesenchymal stromal cell therapies. Sci Transl Med. 2019;11:1‐3.
    1. Orive G, Santos E, Pedraz JL, et al. Application of cell encapsulation for controlled delivery of biological therapeutics. Adv Drug Deliv Rev. 2014;67‐68:3‐14.
    1. Gray A, Maguire T, Schloss R, et al. Identification of IL‐1beta and LPS as optimal activators of monolayer and alginate‐encapsulated mesenchymal stromal cell immunomodulation using design of experiments and statistical methods. Biotechnol Prog. 2015;31:1058‐1070.
    1. Barminko J, Kim JH, Otsuka S, et al. Encapsulated mesenchymal stromal cells for in vivo transplantation. Biotechnol Bioeng. 2011;108:2747‐2758.
    1. Kumar S, Babiarz J, Basak S, et al. Sizes and sufficient quantities of MSC microspheres for intrathecal injection to modulate inflammation in spinal cord injury. Nano Life. 2015;5:1‐14.
    1. Levit RD, Landazuri N, Phelps EA, et al. Cellular encapsulation enhances cardiac repair. J Am Heart Assoc. 2013;2:e000367.
    1. Heile A, Brinker T. Clinical translation of stem cell therapy in traumatic brain injury: the potential of encapsulated mesenchymal cell biodelivery of glucagon‐like peptide‐1. Dialogues Clin Neurosci. 2011;13:279‐286.
    1. Landazuri N, Levit RD, Joseph G, et al. Alginate microencapsulation of human mesenchymal stem cells as a strategy to enhance paracrine‐mediated vascular recovery after hindlimb ischaemia. J Tissue Eng Regen Med. 2012;10:222‐232.
    1. Connick P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open‐label phase 2a proof‐of‐concept study. Lancet Neurol. 2012;11:150‐156.
    1. Baron F, Lechanteur C, Willems E, et al. Cotransplantation of mesenchymal stem cells might prevent death from graft‐versus‐host disease (GVHD) without abrogating graft‐versus‐tumor effects after HLA‐mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant. 2010;16:838‐847.
    1. Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living‐related kidney transplants: a randomized controlled trial. JAMA. 2012;307:1169‐1177.
    1. Weiss DJ, Casaburi R, Flannery R, et al. A placebo‐controlled, randomized trial of mesenchymal stem cells in COPD. Chest. 2013;143:1590‐1598.
    1. Xu J, Wang D, Liu D, et al. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjogren syndrome. Blood. 2012;120:3142‐3151.
    1. Zhang H, Liang J, Tang X, et al. Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis. Arthritis Res Ther. 2017;19:165.
    1. Carlsson PO, Schwarcz E, Korsgren O, et al. Preserved beta‐cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes. 2015;64:587‐592.
    1. Forbes GM, Sturm MJ, Leong RW, et al. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Clin Gastroenterol Hepatol. 2014;12:64‐71.
    1. Butler J, Epstein SE, Greene SJ, et al. Intravenous allogeneic mesenchymal stem cells for nonischemic cardiomyopathy: safety and efficacy results of a phase II—a randomized trial. Circ Res. 2017;120:332‐340.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa